4basebio Past Earnings Performance
Past criteria checks 0/6
4basebio's earnings have been declining at an average annual rate of -45.4%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 5.4% per year.
Key information
-45.4%
Earnings growth rate
-40.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -5.4% |
| Return on equity | n/a |
| Net Margin | -1,514.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How 4basebio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -8 | 5 | 4 |
| 30 Sep 23 | 0 | -7 | 5 | 3 |
| 30 Jun 23 | 0 | -6 | 4 | 3 |
| 31 Mar 23 | 0 | -6 | 4 | 2 |
| 31 Dec 22 | 0 | -5 | 4 | 2 |
| 30 Sep 22 | 0 | -5 | 3 | 2 |
| 30 Jun 22 | 0 | -4 | 2 | 2 |
| 31 Mar 22 | 0 | -4 | 2 | 2 |
| 31 Dec 21 | 0 | -3 | 2 | 2 |
| 30 Sep 21 | 0 | -3 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 2 | 1 |
| 31 Mar 21 | 0 | -1 | 1 | 1 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 1 | -2 | 1 | 1 |
Quality Earnings: 88Q is currently unprofitable.
Growing Profit Margin: 88Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 88Q is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Accelerating Growth: Unable to compare 88Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 88Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.9%).
Return on Equity
High ROE: 88Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.